echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nat Commun: Sarcoma classification tool based on DNA methylation analysis

    Nat Commun: Sarcoma classification tool based on DNA methylation analysis

    • Last Update: 2021-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Sarcoma, as a heterogeneic tumor, is a malignant cartilage and bone tumor that affects adults, adolescents and children.
    because many solid sarcoma lack clear morphological or molecular characteristics, the overall rarity of sarcoma leads to a general lack of experience in diagnosis.
    pathologists often rely on changes in identified tumor-specific molecules for diagnosis.
    , however, the high degree of difference in diagnosis also results in high rates of difference and misclassifying of feedback received by patients between major institutions and specialized referral centres.
    , although specific molecular changes such as gene fusion from trans positions have become the diagnostic criteria for many sarcoma, about half of solid sarcoma lack clear molecular markers.
    , there is an urgent need for novel diagnostic methods to fill the diagnostic gaps described above.
    the establishment of DNA methylation-based sarcoma reference queues is a key predetermined genetic marker that plays a vital role in normal development and disease.
    previous studies have shown that DNA methylation-based analysis shows the potential for diagnosis of cartilage and osteosarcoma subsypes.
    the study, researchers aim to develop a DNA methylation-based classification tool for labeling cartilage and osteosarcoma in various subsypes and age groups.
    cross-validation of DNA methylated sarcoma classifiers The researchers demonstrated the classification of cartilage and osteosarcoma using machine learning classifier algorithms based on array-generated DNA methylated data.
    the classifier was trained with a dataset from 1077 methylated maps from fully pre-indicated cases, including 62... Xiaozeng Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.